FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 180 filers reported holding FATE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,646,208 | -55.6% | 1,248,212 | -0.3% | 0.00% | 0.0% |
Q2 2023 | $5,961,714 | +33.2% | 1,252,461 | +59.5% | 0.00% | 0.0% |
Q1 2023 | $4,476,153 | -41.9% | 785,290 | +2.9% | 0.00% | -50.0% |
Q4 2022 | $7,703,069 | -55.2% | 763,436 | -0.6% | 0.00% | -50.0% |
Q3 2022 | $17,204,000 | -10.5% | 767,700 | -1.1% | 0.00% | 0.0% |
Q2 2022 | $19,227,000 | -36.4% | 775,907 | -0.5% | 0.00% | -20.0% |
Q1 2022 | $30,234,000 | -36.4% | 779,832 | -4.0% | 0.01% | -37.5% |
Q4 2021 | $47,517,000 | -2.6% | 812,107 | -1.4% | 0.01% | -11.1% |
Q3 2021 | $48,802,000 | -36.4% | 823,397 | -6.9% | 0.01% | -35.7% |
Q2 2021 | $76,781,000 | +5.6% | 884,680 | +0.3% | 0.01% | 0.0% |
Q1 2021 | $72,732,000 | -10.5% | 882,122 | -1.3% | 0.01% | -12.5% |
Q4 2020 | $81,234,000 | +121.5% | 893,368 | -2.6% | 0.02% | +100.0% |
Q3 2020 | $36,677,000 | +21.7% | 917,606 | +4.4% | 0.01% | +14.3% |
Q2 2020 | $30,148,000 | +69.7% | 878,695 | +9.9% | 0.01% | +40.0% |
Q1 2020 | $17,762,000 | +14.8% | 799,720 | +1.1% | 0.01% | +66.7% |
Q4 2019 | $15,473,000 | +43.1% | 790,630 | +13.5% | 0.00% | 0.0% |
Q3 2019 | $10,813,000 | -29.2% | 696,320 | -7.5% | 0.00% | -25.0% |
Q2 2019 | $15,280,000 | +16.0% | 752,696 | +0.4% | 0.00% | +33.3% |
Q1 2019 | $13,167,000 | +39.5% | 749,372 | +1.9% | 0.00% | 0.0% |
Q4 2018 | $9,437,000 | -7.2% | 735,512 | +17.8% | 0.00% | +50.0% |
Q3 2018 | $10,174,000 | +57.9% | 624,576 | +9.9% | 0.00% | 0.0% |
Q2 2018 | $6,444,000 | +32.9% | 568,272 | +14.4% | 0.00% | +100.0% |
Q1 2018 | $4,850,000 | +104.3% | 496,919 | +27.9% | 0.00% | 0.0% |
Q4 2017 | $2,374,000 | +52.6% | 388,416 | -1.2% | 0.00% | – |
Q3 2017 | $1,556,000 | +30.4% | 392,950 | +6.7% | 0.00% | – |
Q2 2017 | $1,193,000 | +659.9% | 368,208 | +968.7% | 0.00% | – |
Q1 2017 | $157,000 | +57.0% | 34,455 | -13.4% | 0.00% | – |
Q4 2016 | $100,000 | -17.4% | 39,773 | +3.0% | 0.00% | – |
Q3 2016 | $121,000 | +181.4% | 38,625 | +51.3% | 0.00% | – |
Q2 2016 | $43,000 | -6.5% | 25,531 | 0.0% | 0.00% | – |
Q1 2016 | $46,000 | -46.5% | 25,531 | 0.0% | 0.00% | – |
Q4 2015 | $86,000 | -36.8% | 25,531 | 0.0% | 0.00% | – |
Q3 2015 | $136,000 | -28.8% | 25,531 | -13.3% | 0.00% | – |
Q2 2015 | $191,000 | – | 29,464 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |